Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13462606 | 1.00 | BRD4 (0.38) | BRD4CRHR1CNR2ALDH1A1ALDH3A1 | |
| SCHEMBL13564748 | 0.87 | BRD4 (0.38) | BRD4CRHR1CNR2ALDH1A1ALDH3A1 | |
| SCHEMBL17090297 | 0.87 | BRD4 (0.38) | BRD4CRHR1CNR2ALDH1A1ALDH3A1 | |
| SCHEMBL17090174 | 0.86 | CRHR1 (0.49) | BRD4CRHR1CNR2NPY5R | |
| SCHEMBL13565514 | 0.86 | OPRD1 (0.43) | BRD4CRHR1CNR2ALDH1A1NPY5R | |
| SCHEMBL13438930 | 0.86 | CRHR1 (0.50) | CRHR1CNR2POLB | |
| SCHEMBL11935248 | 0.86 | CRHR1 (0.50) | CRHR1CNR2POLB | |
| SCHEMBL17089962 | 0.86 | OPRD1 (0.43) | BRD4CRHR1CNR2ALDH1A1NPY5R | |
| SCHEMBL13565550 | 0.86 | CRHR1 (0.49) | BRD4CRHR1CNR2NPY5R | |
| SCHEMBL13438902 | 0.85 | CRHR1 (0.44) | CRHR1CNR2ALDH1A1ALDH3A1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | BRD4 1136/4885CRHR1 21/4885CNR2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.